Evidence table for systematic reviews
|
|
- Augustine Sharp
- 5 years ago
- Views:
Transcription
1 Evidence table for systematic reviews Topic: CB use and dependence Reviewer: CMF Abbreviations: y- years Reference Research Parameters Population Outcomes Funding Additional comments Bibliographic reference Research question Theoretical approach Data Study type and quality Population and sample Gender Age Key themes Source of funding Limitations Evidence gap OCEBM level of evidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Degenhardt et al. MA Not reported Not Not 2013 (PLOS) reported reported Contribution of CBuse and dependence to Global Burden of Disease Medline, EMBASE, PsycInfo, handsearched, expert consultation 01/ /2008 Total number of yielded papers not reported 13 epidemiological studies on prevalence of CB dependence, 7 on prevalence of weekly CB use, 80 on prevalence of past year CB use, 3 general population cohort studies on incidence of CBuse and dependence Study quality assessed and reported (in cited earlier publications of this group) > no epidemiological evidence for increased mortality due to CB dependence > global prevalence estimate of CB dependence 0.19% (2010) and 0.2% (1999), corresponds to 13 (2010) and 11 (1999) million cases worldwide > prevalence higher in males (0.23%) than females (0.14%), higher in high-income (Australasia, North America, Western Europe) % than in low and middle income regions %, peaking in 20-24y age-group (max. 0.38% in males, 0.22 in females) and steady decrease thereafter > Western Europe prevalence: total: 0.34%, females: 0.26%, males: 0.46% > CB dependence accounted for 0.08% of global disability-adjusted life years (DALY) in 2010 (0.07% in 1999) corresponding to 2 million DALYs > accounting for 12.5% of years of life lived with disability (YLD) attributed to illicit drug use and 0.27% of global all-cause YLD; globally more DALYs than attributed to cocaine or amphetamine (just in high income regions with available data) > majority of YLD due to CB dependence occurred in 20-24y age range (33.5%, in males 64.3%) > regular CBuse as risk factor for schizophrenia accounted for 7000 DALYs or 0.04% of schizophrenia DALYs globally; more pronounced Australian National Health and Medical Research Council, Australian Government, Queensland Department of Health, Bill and Melinda Gates Foundation > few or missing epidemiological data (maily low income regions) account for considerable uncertainty around estimated rates Gap in existing epidemiological data on CB depedence Methodological rating SIGN 2 High quality ++ 1
2 Reference Research Parameters Population Outcomes Funding Additional comments Bibliographic reference Research question Theoretical approach Data Study type and quality Population and sample Gender Age Key themes Source of funding Limitations Evidence gap OCEBM level of evidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in males than females (5000 vs DALYs) and peaking DALYs between 25-30y of age with subsequent steady decrease Degenhardt et al Degenhardt & Hall 2012 Global coverage of illicit drug use and dependence estimates Summary of prevalence, correlates and probable adverse health effects of problem use of amphetamines, CB, cocaine and opiods MA MA Medline, EMBASE, PsycInfo, LILACS, grey literature Yielded 1857 papers for CB Medline, EMBASE, PsycInfo, handsearched, expert consultation 01/ /2008 Total number of yielded papers not reported 191 data sources (cohort studies, general population epidemiological studies, national estimates of prevalence (183) and incidence (8) Study quality assessed and reported Number of included studies not reported Epidemiological data of cohort studies and representative household surveys Study quality assessed but not reported Representative global population from 201 countries/ territories (>99% of population aged 15-64y) Representative global population (aged 15-64y) Not reported Not reported 15-64y > CBuse or dependence is reported in 201 (from 229) territories/countries representing >99% of global population aged 15-64y > estimates of CBuse from 95 countries, of CB dependence from 7 countries data from Germany (2006) > CBuse prevalence last year 4.7%, lifetime 23% > CB dependence last year prevalence 0.4% (18-64y), lifetime 3.1% (24-34y) 15-64y CBuse > estimate of CBuse: % (2009, global population 15-64y) corresponding to Mio people; highest rates in North America, Western Europe and Oceania > common temporal order of drug initiation in high-income countries: alcohol/tobacco CB other illicit drugs; not consistently evident in all countries > more common in males than females > peaking in young adulthood with subsequent decrease > health-related harm of CB differs qualitatively from other illicit drugs; contributes more to morbidity than mortality; major adverse effect is CB dependence > risk factors for regular CBuse: social contextual factors (drug availability, alcohol/ tobacco use at early age, drug-tolerant social norms, socioeconomic status, poverty, social and cultural factors), family factors (poor quality of parent-child relationship, parental conflict, parental/ sibling drug use), individual risk factors (male, strong novelty/ sensation seeking, oppositional behaviour/ conduct disorder during childhood, poor Australian National Drug and Research Centre (NDARC), Australian National Health and Medical Research Council Not mentioned > regional comparisons of prevalence rates restricted by inconsistent, incomplete, outdated and unclear /reporting > prevalence of CB dependence rarely studied > inconsistent types of measurement between studies (direct vs. indirect estimates> reporting bias) > accuracy of estimated exact magnitude of health, social and financial burden limited due to lacking data > burden of illicit drugs underestimated as not all adverse outcomes included > need for more prospective, quantitative, longitudinal studies of specific patterns of drug use and their specific outcomes > adverse effects of polydrug use (instead of single drug) not clear Methodological rating SIGN 2 High quality ++ 2 High quality ++ 2
3 Reference Research Parameters Population Outcomes Funding Additional comments Bibliographic reference Research question Theoretical approach Data Study type and quality Population and sample Gender Age Key themes Source of funding Limitations Evidence gap OCEBM level of evidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] school performance, low educational commitment, early school leaving), affiliation with peers (antisocial, drug-using) is one of the strongest predictors of adolescent alcohol and further drug use > risk factors co-occur often CB dependence > according to ICD-10/ DSM IV criteria past year prevalence estimate in adults is % (7 countries from North America, Western Europe, Australia, Southeast Asia) > risk factors of illicit drug dependence: earlier age of drug onset, polysubstance use, development of externalizing and internalizing disorders < 15y of age > dependence lifetime risk: 9% for CB (vs. 23% for heroin) Adverse health effects of CB use: > cognitive and behavioral impairments (especially sustained attention) > increased risk of traffic accidents > consistent association of early CBuse onset, regular CBuse and later diagnosis of schizophrenia; CBuse plausible contributory cause of schizophrenia in vulnerable individuals > less consistent association for CBuse and depression > insufficient available evidence for CBuse and suicide > no evidence for CBuse and increased mortality > Degenhardt et al (Lancet) Summary of prevalence and disease burden of illicit drug use from Global Burden of Disease Study 2010 and Comparative Risk Assessment 2002 MA Medline, EMBASE, PsycInfo, handsearched, expert consultation 01/ /2008 Total number of Number of included studies not reported Epidemiological data of cohort studies and representative household surveys Study quality assessed but not reported Representative global population (aged 15-64y) Not reported 15-64y > opioid and amphetamine dependence most common although CB most frequently consumed illicit drug > estimated prevalence of CB dependence: overall 0.19% (13.1 Mio), Australasia/ Northern America/ Western Europe % > CB dependence is estimated to account for overall disability adjusted life-years (DALYs) which all represent years Australian National Health and Medical Research Council, Australian Government Department of Health and Ageing, Bill and Melinda Gates > burden of illicit drugs underestimated as not all adverse outcomes included > evidence of causal link of CBuse and suicide, cancer and accidental injuries to weak to be included > disability measure limited to health outcomes (not social or economic consequences) Methodological rating SIGN 2 High quality ++ 3
4 Reference Research Parameters Population Outcomes Funding Additional comments Bibliographic reference Research question Theoretical approach Data Study type and quality Population and sample Gender Age Key themes Source of funding Limitations Evidence gap OCEBM level of evidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] yielded papers not reported of life lived with disability (YLD), no years of life lost (YLL) due to no signs of increased mortality > mainly attributable to men 64% ( , women ) consistent in all age groups > represents 10.3% of illicit drug dependence burden > fairly consistent age pattern in all illicit drug dependences: sharp increase in DALYs between 15-24y, peak between 20-30y, steady decline thereafter; steepest decline for CB > higher proportion of burden in high-income regions Foundation Calabria et al Remission from dependence upon amphetamines, CB, cocaine and opioids SR Medline, EMBASE, PsycInfo, handsearched, expert consultation 01/ /2009 Yielded 389 papers for CB 3 prospective population based studies included Study quality assessed and reported General population of Australia (138), USA (33) and Germany (37) 26.8% male or not reported Age range: 14-32y > remission rates within single studies: Australia 53% (4y followup), USA 36% (4y follow-up), Germany 82% (10y follow-up) > conservative, pooled estimate for remission of CBdependence: > highest remission rate for CBdependence, followed by amphetamine, opiod and cocaine dependence Australian National Drug and Research Centre (NDARC), Australian National Health and Medical Research Council > limited evidence > definition of remission varies between studies or is not clearly described > great need for more studies in more settings across more countries > impact of polydrug use on remission Methodological rating SIGN 3 High quality ++ Peters et al Clinical diagnoses, psychosocial problems and outcomes associated with co-occurring CB and tobacco use SR Medline, PsycInfo, Pubmed, handsearched Yielded 3029 papers 28 included studies (treatment studies, cross-sectional epidemiological surveys and cohort studies) Study quality not assessed and reported Total N: samples mainly from North America, and Australia,2 from Western Europe Not reported Not reported, adolescent and adult samples > comparison of CB+tobacco (CT) users with only CB (C) or tobacco (T) users: CB use disorder > 11 studies; current and lifetime CBuse in CT (compared to C) associated with increased rates or severity of CB abuse or dependence, more symptoms of CBdependence and withdrawl and increased likelihood of withdrawl symptoms > less reliable data on higher prevalence of CB use disorder or dependence in CT users Tobacco use disorder > inconsistent findings in 5 studies; higher CBuse in CT associated to higher nicotine dependence rates (compared to T) Psychosocial problems National Institute on Drug Abuse (NIDA) > small number of studies > not all studies adjusted for potential confounders (methodological weakness) > variable assessment of CT use and clinical outcomes 2 Acceptable quality + 4
5 Reference Research Parameters Population Outcomes Funding Additional comments Bibliographic reference Research question Theoretical approach Data Study type and quality Population and sample Gender Age Key themes Source of funding Limitations Evidence gap OCEBM level of evidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] > 4 studies; compared to C, Clusers were found to have symptoms of anxiety (unadjusted analysis), educational performance, psychiatric severity and legal problems; contradictory findings for alcohol consumption and depressive symptoms in CT compared to C users > CT compared to T users showed no greater impairments CB use > 3 studies; risk of relapse and more persistent use of CB in CT compared to C users Tobacco use > 8 studies; inconsistent reports on success in quitting smoking in in CT compared to T users Methodological rating SIGN NASEM (2017) Harmful and dependent CU, risk factors for dependence SR Medline, Embase, and the Cochrane Database of Systematic Reviews cross-sectional studies, epidemiological surveys, cohort studies) n.a. Not reported Not reported, adolescen t and adult samples Many different variables (e.g. biological gender, age at CU onset, other substance use, mental disorders) as predictors for problematic and dependent CU Alaska Mental Health Trust Authority; Arizona Department of Health Services; California Department of Public Health; CDC Foundation; Centers for Disease Control and Prevention; The Colorado Health Foundation; Mat-Su Health Foundation; National Highway Traffic Safety Administratio n; National Institutes of Health/ National Cancer Institute; National Risk of bias was assessed, but not reported in the respective chapters. 2 Acceptable quality + 5
6 Reference Research Parameters Population Outcomes Funding Additional comments Bibliographic reference Research question Theoretical approach Data Study type and quality Population and sample Gender Age Key themes Source of funding Limitations Evidence gap OCEBM level of evidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Institutes of Health/Natio nal Institute on Drug Abuse; Oregon Health Authority; the Robert W. Woodruff Foundation; Truth Initiative; U.S. Food and Drug Administratio n; and Washington State Department of Health. Methodological rating SIGN 6
7 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) Calabria et al Systematic review of prospective studies investigating remission from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav Guideline topic: CB use and dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. No No Can t say No Can t say No 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. No
8 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Can t say No No No No 1.12 Conflicts of interest are declared. No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) x Acceptable (+) Low quality (-) Unacceptable reject 0 Yes No
9 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) Degenhardt & Hall 2012 Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet Guideline topic: CB use and dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. No No Can t say No Can t say No 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. Yes No x
10 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Can t say No No No No 1.12 Conflicts of interest are declared. No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) x Acceptable (+) Low quality (-) Unacceptable reject 0 Yes No
11 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) Degenhardt et al What data are available on the extent of illicit drug use and dependence globally? Results from four systematic reviews. Drug Alc Dep Guideline topic: CB use and dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. No No Can t say No Can t say No 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. Yes No x
12 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Can t say No No No No 1.12 Conflicts of interest are declared. No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) x Acceptable (+) Low quality (-) Unacceptable reject 0 Yes No
13 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) Degenhardt et al The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from GBD 2010 Study. Plos Guideline topic: CB use and dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. No No Can t say x No Can t say No 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. Yes No x
14 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Can t say No No No No 1.12 Conflicts of interest are declared. No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) x Acceptable (+) Low quality (-) Unacceptable reject 0 Yes No
15 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) Degenhardt et al Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study Lancet Guideline topic: CB use and dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. No No Can t say No Can t say No 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. Yes No x
16 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Can t say No No No No 1.12 Conflicts of interest are declared. No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) x Acceptable (+) Low quality (-) Unacceptable reject 0 Yes No
17 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) National Academies of Sciences, Engineering, and Medicine The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press Guideline topic: CB dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? Yes x No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. Yes x Yes Yes Yes No No Can t say x No Can t say x No x 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. Yes x No
18 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Yes x Yes x Yes Can t say Yes x No No No x No 1.12 Conflicts of interest are declared. Yes x No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) Acceptable (+)X Low quality (-) Unacceptable reject 0 Yes No
19 S I G N Methodology Checklist 1: Systematic Reviews and Metaanalyses SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi: / Available from [cited 10 Sep 2012] Study identification (Include author, title, year of publication, journal title, pages) Peters, Budney & Carroll 2012 Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addict Rev Guideline topic: CB use and dependence Key Question No: Before completing this checklist, consider: Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO reject. IF YES complete the checklist. Checklist completed by: CMF Section 1: Internal validity In a well conducted systematic review: 1.1 The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. Does this study do it? No 1.2 A comprehensive literature search is carried out. 1.3 At least two people should have selected studies. 1.4 At least two people should have extracted data. 1.5 The status of publication was not used as an inclusion criterion. Yes Yes Yes No No Can t say x No Can t say x No x 1.6 The excluded studies are listed. Yes No x 1.7 The relevant characteristics of the included studies are provided. No
20 1.8 The scientific quality of the included studies was assessed and reported. 1.9 Was the scientific quality of the included studies used appropriately? 1.10 Appropriate methods are used to combine the individual study findings The likelihood of publication bias was assessed appropriately. Yes Yes Can t say Yes x No x No No x No 1.12 Conflicts of interest are declared. No SECTION 2: OVERALL ASSESSMENT OF THE STUDY 2.1 What is your overall assessment of the methodological quality of this review? 2.2 Are the results of this study directly applicable to the patient group targeted by this guideline? 2.3 Notes: High quality (++) x Acceptable (+) Low quality (-) Unacceptable reject 0 Yes No
Evidence table for systematic reviews
Evidence table for systematic reviews Topic: Cannabis and Cognition Reviewer: CMF, MS Abbreviations: : reduced; : increased; : not altered; abstin: abstinence; adol: adolescent; CB: cannabis; CI: confidence
More informationEvidence table for systematic reviews
Evidence table for systematic reviews Topic: synthetic Cannabinoids Reviewer: CMF, MS Abbreviations: CB cannabis, ER emergency room, etoh ethanol, f female, m male, SC synthetic cannabinoid, SR systematic
More informationThe Link between Marijuana &
The Link between Marijuana & mental illness A Survey of Recent Research OFFICE OF NATIONAL DRUG CONTROL POLICY EXECUTIVE OFFICE OF THE PRESIDENT July 2007 TABLE OF CONTENTS Overview of Marijuana and Mental
More informationMarijuana and tobacco use among young adults in Canada: are they smoking what we think they are smoking?
DOI 10.1007/s10552-006-0103-x ORIGINAL PAPER Marijuana and tobacco use among young adults in Canada: are they smoking what we think they are smoking? Scott T. Leatherdale Æ David G. Hammond Æ Murray Kaiserman
More informationPublic Mental Health. Benedetto Saraceno University Nova of Lisbon University of Geneva Chairman Global Initiative on Psychiatry, The Netherlands
Public Mental Health Benedetto Saraceno University Nova of Lisbon University of Geneva Chairman Global Initiative on Psychiatry, The Netherlands FIVE KEY POINTS IN PMH Mental disorders: high prevalence
More informationThe Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research
Stakeholder Meeting for the National Academies Report: The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research Study Sponsors Alaska Mental Health
More informationParental supply of alcohol and adolescent drinking, harms, and alcohol use disorder symptoms: Six years later Richard P Mattick et al.
Parental supply of alcohol and adolescent drinking, harms, and alcohol use disorder symptoms: Six years later Richard P Mattick et al. Australian Parental Supply of Alcohol Longitudinal Study (APSALS)
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationOVERDOSE DEATHS IN AUSTRALIA COCAINE AND METHAMPHETAMINE MENTIONS IN ACCIDENTAL DRUG-INDUCED DEATHS IN AUSTRALIA,
VERDSE DEATHS IN AUSTRALIA 2002 Edition CCAINE AND METHAMPHETAMINE MENTINS IN ACCIDENTAL DRUG-INDUCED DEATHS IN AUSTRALIA, 1997-2002 Recent years have seen an increase in the number of persons sampled
More informationTRENDS IN SUBSTANCE USE AND ASSOCIATED HEALTH PROBLEMS
Fact Sheet N 127 August 1996 TRENDS IN SUBSTANCE USE AND ASSOCIATED HEALTH PROBLEMS Psychoactive substance use is an increasing public health concern. Problems associated with this use cover a broad spectrum
More informationJan. 12, 2017 FOR IMMEDIATE RELEASE
Jan. 12, 2017 FOR IMMEDIATE RELEASE Nearly 100 Conclusions on the Health Effects of Marijuana and Cannabis-Derived Products Presented in New Report; One of the Most Comprehensive Studies of Recent Research
More informationThe Scottish Burden of Disease Study, Drug use disorders technical overview
The Scottish Burden of Disease Study, 2016 Drug use disorders technical overview This resource may also be made available on request in the following formats: 0131 314 5300 nhs.healthscotland-alternativeformats@nhs.net
More informationMagnitude. SELECT A TOPIC...
Page 1 of 6 SELECT A TOPIC..... NIDA Home > Drug Abuse and Addiction: One of America's Most Challenging Public Health Problems Magnitude Drug Abuse is Costly Drug abuse is a major public health problem
More informationTaking Stock of the 2009 PoA Research and Trend Analysis Branch
Taking Stock of the 2009 PoA Research and Trend Analysis Branch Eliminate or reduce significantly and measurably: The five targets Illicit cultivation of opium, coca, cannabis Illicit demand of drugs and
More informationPERSPECTIVES ON DRUGS Characteristics of frequent and high-risk cannabis users
European Monitoring Centre for Drugs and Drug Addiction UPDATED 28. 5. 2013 PERSPECTIVES ON DRUGS Characteristics of frequent and high-risk cannabis users Cannabis is Europe s most commonly used illicit
More informationScientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances
page 1/5 Scientific Facts on Psychoactive Drugs Tobacco, Alcohol, and Illicit Substances Source document: WHO (2004) Summary & Details: GreenFacts Context - Psychoactive drugs such as tobacco, alcohol,
More informationPrevalence of Marijuana Use among University Students in Bolivia, Colombia, Ecuador, and Peru
Int. J. Environ. Res. Public Health 2015, 12, 5233-5240; doi:10.3390/ijerph120505233 OPEN ACCESS Article International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph
More informationCocaine and Methamphetamine related drug-induced deaths in Australia, 2011
Cocaine and Methamphetamine related drug-induced deaths in Australia, 2011 Recommended citation: Roxburgh, A. and Burns, L (2015). Cocaine and methamphetamine related drug-induced deaths in Australia,
More informationDrug-related hospital stays in Australia
Drug-related hospital stays in Australia 1993-213 Prepared by Amanda Roxburgh and Lucinda Burns, National Drug and Alcohol Research Centre Funded by the Australian Government Department of Health Introduction
More informationCigarette Consumption in China ( ) Cigarette Consumption in Poland ( )
Section C Global Burden Global Smoking Prevalence Source: adapted by CTLT from The Tobacco Atlas. (2006). 2 1 Cigarette Consumption in China (1952 1996) Average Number of Manufactured Cigarettes Smoked
More informationAppendix A: Literature search strategy
Appendix A: Literature search strategy The following databases were searched: Cochrane Library Medline Embase CINAHL World Health organisation library Index Medicus for the Eastern Mediterranean Region(IMEMR),
More informationShould buprenorphine be covered for maintenance treatment in opioid dependent persons?
Prepared by: Silvia Pregno May 13,2012 Patients: people with opioid dependence Should buprenorphine be covered for maintenance treatment in opioid dependent persons? Intervention: buprenorphine Comparison:
More informationTITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines
TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 17 January 2014 CONTEXT AND POLICY ISSUES Obstructive sleep apnea (OSA) is a common
More informationBurden and cost of alcohol, tobacco and illegal drugs globally and in Europe
Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe Jürgen Rehm 1-4 Kevin D. Shield 1,2,3 1) Centre for Addiction and Mental Health, Toronto, Canada 2) University of Toronto, Canada
More informationJerisha Ellerstrand, Alize Ferrari, Louisa. Degenhardt, Harvey Whiteford & Janni Leung. A systematic review of the global prevalence of
Jerisha Ellerstrand, Alize Ferrari, Louisa Degenhardt, Harvey Whiteford & Janni Leung A systematic review of the global prevalence of prescription opioid non-medical use with an estimate of prescription
More informationDrug-related hospital stays in Australia
Drug-related hospital stays in Australia 1993 2012 Prepared by Funded by Amanda Roxburgh and Lucy Burns, National Drug and Alcohol Research Centre the Australian Government Department of Health and Ageing
More informationEvidence Summary For the Ghana Essential Medicines Committee
Evidence Summary For the Ghana Essential Medicines Committee Title: Caffeine Citrate for treating apnoea in preterm infants Formulation: 1. Injection: 20 mg/ml (equivalent to 10 mg caffeine base/ml) 2.
More informationBertha K Madras, PhD Professor of Psychobiology Department of Psychiatry Harvard Medical School McLean Hospital
Bertha K Madras, PhD Professor of Psychobiology Department of Psychiatry Harvard Medical School McLean Hospital bmadras@partners.org Users The Brain Adolescent Marijuana Safety Marijuana and Opioids Protecting
More informationOverview of the Australian National Drug Strategy Household Survey (NDSHS)
Overview of the Australian National Drug Strategy Household Survey (NDSHS) Marian Shanahan and Amanda Roxburgh NDARC, University of New South Wales, Australia EMCDDA June 2012 Overview About the survey
More information2002 AUSTRALIAN BUREAU OF STATISTICS DATA ON ACCIDENTAL DRUG-INDUCED DEATHS DUE TO OPIOIDS
OPIOID OVERDOSE DEATHS IN AUSTRALIA 2002 Edition 2002 AUSTRALIAN BUREAU OF STATISTICS DATA ON ACCIDENTAL DRUG-INDUCED DEATHS DUE TO OPIOIDS O This bulletin provides data on accidental opioid deaths in
More informationSubstance use in young people 2 Why young people s substance use matters for global health
Substance use in young people 2 Why young people s substance use matters for global health Wayne D Hall, George Patton, Emily Stockings, Megan Weier, Michael Lynskey, Katherine I Morley, Louisa Degenhardt
More informationDrug related hospital stays in Australia
Prepared by Funded by Amanda Roxburgh and Courtney Breen, National Drug and Alcohol Research Centre the Australian Government Department of Health Recommended Roxburgh, A. and Breen, C (217). Drug-related
More informationCANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE
1 CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More informationThe Burden of Heart Failure in the Asia Pacific. Eugenio B. Reyes, M.D. Associate Professor, University of the Philippines, College of Medicine
The Burden of Heart Failure in the Asia Pacific Eugenio B. Reyes, M.D. Associate Professor, University of the Philippines, College of Medicine Q1. The most prevalent risk factor for heart failure in the
More informationVulnerability and drug prevention
Vulnerability and drug prevention Margareta Nilson Gregor Burkhart, Gilberto Gerra Mental Health of children and adolescents Luxembourg, 20-21 September 2004 Vulnerability and drug prevention Prevention
More informationCeasing cannabis use during the peak period of experimentation:
Ceasing cannabis use during the peak period of experimentation: A prospective study of the substance use and mental health outcomes of young adult cannabis users and former users Silins, E. 1, Swift, W.
More informationAlcoholism: Community aspects and social perspective
Alcoholism: Community aspects and social perspective Dr. Navya Krishna.N 1 st year PG Department of Community Medicine Outline Introduction Definitions Problem statement Social factors leading to Alcoholism
More informationSubstance Use and Addictive Disorders
Key Dates TU Feb 14 Unit 8 147-end and Unit 9; MW Ch 8 Jeffrey and Ch 10 Diana TH Feb 16 Unit 10; MW Ch 11 Theodore B TU Feb 21 Monday class schedule TH Feb 23 Begin Dimensions-Cognition, Units IIC and
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationEDRS. trends. bulletin. Alcohol use disorders amongst a group of regular ecstasy users. Key findings. july Introduction.
ecstasy and related drug trends july 2011 bulletin Authors: Sheena Arora and Lucy Burns, National Drug and Alcohol Research Centre, University of New South Wales Suggested citation: Arora, S. & Burns,
More informationSubstance use in young people 1 The increasing global health priority of substance use in young people
Substance in young people 1 The increasing global health priority of substance in young people Louisa Degenhardt, Emily Stockings, George Patton, Wayne D Hall, Michael Lynskey Substance in young people
More informationSubstance Abuse in US and Europe
Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health Professor, University of Colorado School of Medicine Supply of Legal Opioid Analgesics
More informationWHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Dependence potential:
More informationGlobal drug trends and sustainable development
Lau Global drug trends and sustainable development Chloé Carpentier Chief, Drug Research Section UNODC Göteborg, 15 November 2017 Global trends in estimated number of drug users and people with drug user
More informationPART 1: EVIDENCE REVIEW. Population/ Intervention / Comparison / Outcome (PICO)
CH 6: Community-based rehabilitation for adults with developmental disorders including intellectual disabilities and autism spectrum disorders. [New 2015] [New 2015] SCOPING QUESTION: What is the effectiveness
More informationThe Effects of Maternal Alcohol Use and Smoking on Children s Mental Health: Evidence from the National Longitudinal Survey of Children and Youth
1 The Effects of Maternal Alcohol Use and Smoking on Children s Mental Health: Evidence from the National Longitudinal Survey of Children and Youth Madeleine Benjamin, MA Policy Research, Economics and
More informationEMBARGOED NOT FOR RELEASE PRIOR TO AM WEDNESDAY OCTOBER
Media Release National Drug and Alcohol Research Centre EMBARGOED NOT FOR RELEASE PRIOR TO 12.05 AM WEDNESDAY OCTOBER 14 2015 Crystal methamphetamine use increases by six per cent among people who inject
More informationCharacteristics and Predictors of Recidivist Drink-Drivers
Characteristics and Predictors of Recidivist Drink-Drivers Christine M. Wickens, Rosely Flam-Zalcman, Robert E. Mann, Gina Stoduto, Chloe Docherty, & Rita K. Thomas Remedial Programs Aim - to reduce risk
More informationQuality and Reporting Characteristics of Network Meta-analyses: A Scoping Review
Quality and Reporting Characteristics of Network Meta-analyses: A Scoping Review Andrea C. Tricco MSc, PhD Scientist, Li Ka Shing Knowledge Institute of St. Michael s Hospital Assistant Professor, Dalla
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationSUBSTANCE USE DISORDER IN ADOLESCENT POPULATION
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION ANNABELLE SIMPSON, MD UNIVERSITY OF WASHINGTON GENERAL DISCLOSURES
More informationAddiction, health and treatment interventions
Addiction, health and treatment interventions J. Rehm Social and Epidemiological Research (SER) Department, Centre for Addiction and Mental Health, Toronto, Canada Dalla Lana School of Public Health, University
More informationThe Adverse Consequences of Cannabis Use: Summary of Findings from the. Christchurch Health & Development Study. David M.
The Adverse Consequences of Cannabis Use: Summary of Findings from the Christchurch Health & Development Study David M. Fergusson Christchurch Health & Development Study Department of Psychological Medicine
More informationDOWNLOAD PDF PREVENTING DRUG USE AMONG YOUTH THROUGH COMMUNITY OUTREACH
Chapter 1 : Preventing Drug Misuse and Addiction: The Best Strategy National Institute on Drug Abuse (N Congress directed the military to establish pilot community outreach programs to reduce the demand
More information6/19/2014. Typhoid fever disease burden estimates. Methods: Revisiting the global burden of typhoid fever. Methodology- Ivanoff et al.
Typhoid fever disease burden estimates Methods: Revisiting the global burden of typhoid fever Dr. Vittal Mogasale, MBBS, MPH, PhD International Vaccine Institute Ivanoff et al. (1994): 16.6 million cases
More informationDual Diagnosis. Themed Review Report 2006/07 SHA Regional Reports East Midlands
Dual Diagnosis Themed Review Report 2006/07 SHA Regional Reports East Midlands Contents Foreword 1 Introduction 2 Recommendations 2 Themed Review 06/07 data 3 Additional information 13 Weighted population
More informationHIV and Drug Use Research Fellowship. Programme and Application Webinar
HIV and Drug Use Research Fellowship Programme and Application Webinar Programme and Application Webinar HIV and Drug Use Research Fellowship Programme Intersection of HIV and Drug Use Objectives and Expected
More informationCenters for Disease Control and Prevention
This document is scheduled to be published in the Federal Register on 12/11/2018 and available online at https://federalregister.gov/d/2018-26708, and on govinfo.gov Billing Code: 4163-18-P DEPARTMENT
More informationALCOHOL S BURDEN (with special attention to Africa and the NCDs)
ALCOHOL S BURDEN (with special attention to Africa and the NCDs) Isidore S. Obot, PhD, MPH Professor of Psychology, University of Uyo Director, Centre for Research and Information on Substance Abuse (CRISA),
More informationADHD & Addictions -What We Know
ADHD & Addictions -What We Know Dr. David Teplin, Psy.D., C.Psych. 4th CADDAC Annual Conference, Toronto October 14, 2012 1 Introduction Adult ADHD commonly co-exists with several other disorders, including
More informationAccidental drug-induced deaths due to opioids in Australia, 2013
Prepared by Funded by Product of Amanda Roxburgh and Lucy Burns, National Drug and Alcohol Research Centre the Australian Government Department of Health the National Illicit Drug Indicators Project Recommended
More informationRethinking trauma as a global
as a global challenge Duncan Pedersen Douglas Mental Health University Institute McGill University Autumn 2011 Outline Violence as a public health problem Traumatic injuries Global fatalities and fatal
More informationInitial Report of Oregon s State Epidemiological Outcomes Workgroup. Prepared by:
Illicit Drug Consumption and Consequences in Oregon Prepared by: Addictions & Mental Health Division 5 Summer Street NE Salem, OR 9731-1118 To the reader, This report is one of three epidemiological profiles
More informationThe Global Burden of Foodborne Disease: Overview and Implications. Arie Havelaar on behalf of FERG
The Global Burden of Foodborne Disease: Overview and Implications Arie Havelaar on behalf of FERG Summary FERG: why, what, how? Global overview of burden of foodborne disease Regional differences Policy
More informationPERSPECTIVES ON DRUGS Emergency health consequences of cocaine use in Europe
UPDATED 16. 5. 2014 PERSPECTIVES ON DRUGS Emergency health consequences of cocaine use in Europe Every year, several thousands of cocainerelated emergencies are reported in Europe, along with hundreds
More informationIntroduction to Preventing Intimate Partner and Sexual Violence against Women. Violence and Injury Prevention Short Course
Introduction to Preventing Intimate Partner and Sexual Violence against Women Primary Resource The information in this presentation is largely based on Preventing intimate partner and sexual violence against
More informationWhere is WHO heading? Which interactions of research agenda and policy?
Where is WHO heading? Which interactions of research agenda and policy? V. Poznyak, MD, PhD Coordinator, Management of Substance Abuse Department of Mental Health and Substance Abuse e WHO strategy on
More informationPROTOCOLS AND PRISMA DIAGRAMS
A5 APPENDIX 5: PROTOCOLS AND PRISMAS APPENDIX 5 PROTOCOLS AND PRISMA DIAGRAMS A5.1 Physical Activity Public Health Wales Phase 1 Implementation Programme Report Appendix 5 Protocol for physical activity
More informationResults. NeuRA Forensic settings April 2016
Introduction Prevalence quantifies the proportion of individuals in a population who have a disease during a specific time period. Many studies have reported a high prevalence of various health problems,
More informationStatistics on Drug Misuse: England, 2008
Statistics on Drug Misuse: England, 2008 Summary This annual statistical report presents information on drug misuse among both adults and children. It includes a focus on young adults. The topics covered
More informationCANNABIS IN ONTARIO S COMMUNITIES
CANNABIS IN ONTARIO S COMMUNITIES That municipal governments support their local Public Health Unit and encourage Develop a funded public health approach to cannabis legalization, regulation, restriction
More informationYouth Marijuana Prevention Strategies
June 2018 Youth Marijuana Prevention Strategies PREPARED FOR THRIVE Mat-Su United Way of Mat-Su PREPARED BY Youth Marijuana Prevention Strategies Prepared for: Prepared by: McDowell Group Anchorage Office
More informationCultural Factors that Protect Against Substance Misuse and Promote Mental Health in American Indian and Alaska Native Populations
Cultural Factors that Protect Against Substance Misuse and Promote Mental Health in American Indian and Alaska Native Populations MARCH 2018 RESOURCE OVERVIEW Mental Health in American Indian and Alaska
More informationProject ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D.
Project ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D. High Levels Of Tobacco Use Almost twice as likely to smoke as people without disorders (36.1%
More informationGRADE, Summary of Findings and ConQual Workshop
GRADE, Summary of Findings and ConQual Workshop To discuss Introduction New JBI Levels of Evidence and Grades of Recommendation Moving towards GRADE Summary of Findings tables Qualitative Levels Conclusion
More informationUSDA Nutrition Evidence Library: Systematic Review Methodology
USDA Nutrition Evidence Library: Systematic Review Methodology Julie E. Obbagy, PhD, RD USDA Center for Nutrition Policy & Promotion Meeting #2 October 17, 2016 The National Academies of Sciences, Engineering,
More informationSUBSTANCE ABUSE A Quick Reference Handout by Lindsey Long
Substance Abuse 1 SUBSTANCE ABUSE A Quick Reference Handout by Lindsey Long Diagnostic Criteria (APA, 2004) Within a 12 month period, a pattern of substance use leading to significant impairment or distress
More informationReferences to Argentina Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS
References to Argentina Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS A. EXTENT OF ILLICIT DRUG USE AND HEALTH CONSEQUENCES The global picture Cocaine In 2010, the regions with a
More informationSupervised Injection Services: Evidence and Practice
January 30 th, 2018 12:00 p.m. 1 p.m. (EDT) Supervised Injection Services: Evidence and Practice Mary Clare Kennedy, MA, PhD (cand) - University of British Columbia, BC Centre on Substance Use Tim Gauthier,
More informationMental Health Theme. Aim: to predicting who is most at risk of mental illness and develop novel approaches to prevention and treatment.
Mental Health Theme Aim: to predicting who is most at risk of mental illness and develop novel approaches to prevention and treatment. Psychosis Zammit, Rai, Munafo, Penton-Voak, Lewis Self-harm / suicide
More informationViolence, abuse and mental health in England
October 2015 Violence, abuse and mental health in England Population patterns Responding effectively to violence and abuse (REVA project) Briefing 1 Summary New analysis of national survey data shows that
More informationDisclosure 8/27/2014. Smoking and Substance Abuse in Individuals. ADHD and Drug Abuse
Smoking and Substance Abuse in Individuals with Brooke Molina, Ph.D. University of Pittsburgh Jessica Rhodes, Ph.D. University of Pittsburgh Disclosure Brooke Molina and Jessica Rhodes have no actual or
More informationDialectical Behaviour Therapy in an Outpatient Drug and Alcohol Setting
Dialectical Behaviour Therapy in an Outpatient Drug and Alcohol Setting Distinguishing features of DBT Implementing DBT within Drug Health Services RPAH Case Study Background to DBT Developed in early
More informationAddiction and Substance Abuse among Nevada Youths
Reports Social Health of 2012 Addiction and Substance Abuse among Youths An-Pyng Sun University of, Las Vegas, an-pyng.sun@unlv.edu Chih-Hsiang Ho University of, Las Vegas, chho@unlv.nevada.edu Larry Ashley
More informationADOLESCENT SUBSTANCE ABUSE & THE FAMILY
ADOLESCENT SUBSTANCE ABUSE & THE FAMILY KARA S. BAGOT, M.D. UNIVERSITY OF CALIFORNIA, SAN DIEGO OVERVIEW HBO ADDICTION -VIDEO EPIDEMIOLOGY OF ADOLESCENT SUBSTANCE USE ADOLESCENT NEURODEVELOPMENT COMORBID
More informationMaryland s Behavioral Health Crisis. The Hospital Perspective
Maryland s Behavioral Health Crisis The Hospital Perspective Topics to Cover The National Experience Maryland s Experience Hospital Data 2 The National Experience 3 Behavioral and Physical Health are Linked
More informationStatistics on Drug Misuse: England, 2007
Statistics on Drug Misuse: England, 2007 Summary For the first time, this annual statistical bulletin presents information on drug misuse among both adults and children. The topics covered include: Prevalence
More informationRisks of alcohol-attributable hospitalisation and death in Australia over time: Evidence of divergence by region, age and sex
Risks of alcohol-attributable hospitalisation and death in Australia over time: Evidence of divergence by region, age and sex Richard Pascal, Wenbin Liang, William Gilmore, Tanya Chikritzhs National Drug
More informationCONSEQUENCES OF MARIJUANA USE FOR DEPRESSIVE DISORDERS. Master s Thesis. Submitted to: Department of Sociology
CONSEQUENCES OF MARIJUANA USE FOR DEPRESSIVE DISORDERS Master s Thesis Submitted to: Department of Sociology Virginia Polytechnic Institute and State University In partial fulfillment of the requirement
More informationWHAT SHOULD WE KNOW ABOUT MARIJUANA
WHAT SHOULD WE KNOW ABOUT MARIJUANA Marijuana is the most commonly used illicit drug in the U.S. The use of marijuana can produce adverse physical, mental, emotional, and behavioral effects. What is marijuana?
More informationSleep evaluation scales and questionnaires (Lomeli, H.A. et al, 2008) Abstract
PMSIG Research: Abstracts, Articles and Reviews November 2017 Topic : Pain and Sleep Topics Every other month, the Pain Management Special Interest Group will be providing with some updates on new topics,
More informationIs cannabis addictive? CANNABIS EVIDENCE BRIEF
Is cannabis addictive? CANNABIS EVIDENCE BRIEF BRIEFS AVAILABLE IN THIS SERIES: Is cannabis safe to use? Facts for youth aged 13 17 years. Is cannabis safe to use? Facts for young adults aged 18 25 years.
More informationDrug Related Deaths in Highland
Drug Related Deaths in Highland Carolyn Hunter-Rowe Research and Intelligence Specialist August 2017 Highland Alcohol and Drugs Partnership Larch House, Stoneyfield Business Park, Inverness, IV2 7PA Website:
More informationPatterns of binge drinking among adults in urban and rural areas of Pha-An township, Myanmar
Patterns of binge drinking among adults in urban and rural areas of Pha-An township, Myanmar Saw Morgan Soe Win 1, Chitlada Areesantichai 2. 1 College of Public Health Sciences, Chulalongkorn University,
More informationAnimal-assisted therapy
Introduction Animal-assisted interventions use trained animals to help improve physical, mental and social functions in people with schizophrenia. It is a goal-directed intervention in which an animal
More informationDRINKING A REPORT ON DRINKING IN THE SECOND DECADE OF LIFE IN EUROPE AND NORTH AMERICA
UNDERAGE DRINKING A REPORT ON DRINKING IN THE SECOND DECADE OF LIFE IN EUROPE AND NORTH AMERICA Edited by Philippe De Witte and Mack C. Mitchell Jr. INTRODUCTION The complexity and importance of underage
More informationJSNA Substance Misuse
JSNA Substance Misuse Introduction 9.1. Substance misuse causes less damage to health in absolute population terms than tobacco or alcohol. However, its association with crime and antisocial behaviour
More informationPOLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER
More information